Metabolic engineering of Escherichia coli for production of salicylate 2-O-β-d-glucoside.
- Author:
Ruosong LI
1
;
Yanfeng PENG
2
;
Long MA
1
;
Qinhong WANG
2
Author Information
- Publication Type:Journal Article
- Keywords: Escherichia coli; metabolic engineering; salicylate; salicylate 2-O-β-d-glucoside
- MeSH: Escherichia coli/genetics*; Glucosides; Metabolic Engineering; Salicylic Acid; Pyruvic Acid
- From: Chinese Journal of Biotechnology 2023;39(8):3290-3301
- CountryChina
- Language:Chinese
- Abstract: Salicylate 2-O-β-d-glucoside (SAG) is a derivative of salicylate in plants. Recent reports showed that SAG could be considered as a potential anti-inflammatory substance due to its anti-inflammatory and analgesic effects, and less irritation compared with salicylic acid and aspirin. The biological method uses renewable resources to produce salicylic acid compounds, which is more environmentally friendly than traditional industry methods. In this study, Escherichia coli Tyr002 was used as the starting strain, and a salicylic acid producing strain of E. coli was constructed by introducing the isochorismate pyruvate lyase gene pchB from Pseudomonas aeruginosa. By regulating the expression of the key genes in the downstream aromatic amino acid metabolic pathways, the titer of salicylic acid reached 1.05 g/L in shake flask fermentation. Subsequently, an exogenous salicylic acid glycosyltransferase was introduced into the salicylic acid producing strain to glycosylate the salicylic acid. The newly engineered strain produced 5.7 g/L SAG in shake flask fermentation. In the subsequent batch fed fermentation in a 5 L fermentation tank, the titer of SAG reached 36.5 g/L, which is the highest titer reported to date. This work provides a new route for biosynthesis of salicylate and its derivatives.
